ClinicalTrials.gg
TerminatedNCT06128369OPTIMIZE-2Updated Jul 30, 2026Results posted

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

A Phase 3 interventional study of OCS-01 and Vehicle in Inflammation Eye Pain and Postoperative Cataract, sponsored by Oculis. Terminated at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Oculis · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision to close study due to third-party administrative error preventing analysis of trial results. There was no issue in terms of quality of the investigational product, and no safety risk to any study participant.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
143rd of 322
117 · median 100
Started
2023
with 27 others
Phase 3
57 of 456
4 open now
Registered
377th of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 143rd largest by enrollment of the 322 interventional ones that give a count, is one of 28 that started in 2023, is one of 57 in phase 3, and was the 377th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.

03

Conditions studied

  • Inflammation Eye Pain
  • Postoperative Cataract

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be planning to undergo unilateral cataract extraction via phacoemulsification and posterior chamber intraocular lens (PCIOL) implantation in the study eye.
  • Have a pin-hole visual acuity (VA) without any other correction > 20 letters (approximately 20/400) in the operative eye and > 35 letters (approximately 20/200) in the fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart at Visit 1 (Day -1 to Day -28 [prior to surgery]).

Exclusion criteria

Exclusion Criteria:

  • Have any intraocular inflammation (e.g., white blood cells or flare) present in either eye at the Visit 1 (Day -1 to Day -28 [prior to surgery]) slit-lamp examination.
  • Have a score > 0 on the Ocular Pain Assessment at Visit 1 (Day -1 to Day -28 [prior to surgery]) in the study eye.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    OCS-01

    1 drop of OCS-01 (Dexamethasone ophthalmic suspension, 1.5% \[15 mg/mL\]) in the study eye once daily (QD) for 14 days, beginning 1-day post-surgery in the study eye.

    Drug: OCS-01

  • Placebo comparator
    Vehicle

    1 drop of vehicle in the study eye QD for 14 days, beginning 1-day post-surgery in the study eye.

    Drug: Vehicle

Interventions

  • DrugOCS-01

    Dexamethasone ophthalmic suspension, 1.5%

  • DrugVehicle

    Vehicle

06

What researchers measure

Primary outcomes

  1. Absence of Anterior Chamber Cells at Visit 6.

    Time frame: Day 15.

  2. Absence of Ocular Pain at Visit 4.

    Time frame: Day 4.

Secondary outcomes

  1. Absence of Anterior Chamber Cells at Visits 4 and 5.

    Time frame: Days 4 and 8.

  2. Absence of Ocular Pain at Visits 3, 5, and 6.

    Time frame: Days 2, 8, and 15.

  3. Absence of Flare at Visits 4, 5, and 6.

    Time frame: Days 4, 8, and 15.

  4. Absence of Both Anterior Chamber Cells and Flare at Visits 4, 5, and 6.

    Time frame: Days 4, 8, and 15.

  5. Use of Rescue Medication on or Prior to Each Visit.

    Time frame: Days 1, 2, 4, 8, 15, and 22.

  6. Use of Rescue Medication Overall.

    Time frame: From first dose until Day 22.

07

Results

Posted Jul 30, 2026
Limitations and caveats
The study was terminated due to sponsor decision based on a third party administrative error. As a result, efficacy endpoints are presented descriptively using the safety population defined by treatment received.

Participant flow

Participant flow — Overall Study
MilestoneOCS-01Vehicle
Started6750
Completed6750
Not completed00

Outcome measures

PrimaryAbsence of Anterior Chamber Cells at Visit 6.
Time frame:
Day 15.
Reported as:
Count of participants · Participants
Absence of Anterior Chamber Cells at Visit 6.
ParticipantsOCS-01Vehicle
Absence of Anterior Chamber Cells at Visit 6.4015
PrimaryAbsence of Ocular Pain at Visit 4.
Time frame:
Day 4.
Reported as:
Count of participants · Participants
Absence of Ocular Pain at Visit 4.
ParticipantsOCS-01Vehicle
Absence of Ocular Pain at Visit 4.5126
SecondaryAbsence of Anterior Chamber Cells at Visits 4 and 5.
Time frame:
Days 4 and 8.
Reported as:
Count of participants · Participants
Absence of Anterior Chamber Cells at Visits 4 and 5.
ParticipantsOCS-01Vehicle
Absence of Anterior Chamber Cells at Visit 482
Absence of Anterior Chamber Cells at Visit 5174
SecondaryAbsence of Ocular Pain at Visits 3, 5, and 6.
Time frame:
Days 2, 8, and 15.
Reported as:
Count of participants · Participants
Absence of Ocular Pain at Visits 3, 5, and 6.
ParticipantsOCS-01Vehicle
Absence of Ocular Pain at Visit 34323
Absence of Ocular Pain at Visit 55932
Absence of Ocular Pain at Visit 66741
SecondaryAbsence of Flare at Visits 4, 5, and 6.
Time frame:
Days 4, 8, and 15.
Reported as:
Count of participants · Participants
Absence of Flare at Visits 4, 5, and 6.
ParticipantsOCS-01Vehicle
Absence of Flare at Visit 44731
Absence of Flare at Visit 55336
Absence of Flare at Visit 66644
SecondaryAbsence of Both Anterior Chamber Cells and Flare at Visits 4, 5, and 6.
Time frame:
Days 4, 8, and 15.
Reported as:
Count of participants · Participants
Absence of Both Anterior Chamber Cells and Flare at Visits 4, 5, and 6.
ParticipantsOCS-01Vehicle
Absence of Both Anterior Chamber Cells and Flare at Visit 481
Absence of Both Anterior Chamber Cells and Flare at Visit 5174
Absence of Both Anterior Chamber Cells and Flare at Visit 64015
SecondaryUse of Rescue Medication on or Prior to Each Visit.
Time frame:
Days 1, 2, 4, 8, 15, and 22.
Reported as:
Count of participants · Participants
Use of Rescue Medication on or Prior to Each Visit.
ParticipantsOCS-01Vehicle
Use of Rescue Medication at Visit 200
Use of Rescue Medication at Visit 301
Use of Rescue Medication at Visit 412
Use of Rescue Medication at Visit 5620
Use of Rescue Medication at Visit 61129
Use of Rescue Medication at Visit 71630
SecondaryUse of Rescue Medication Overall.
Time frame:
From first dose until Day 22.
Reported as:
Count of participants · Participants
Use of Rescue Medication Overall.
ParticipantsOCS-01Vehicle
Use of Rescue Medication Overall.1630

Adverse events

Collected over From first dose until Day 22.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OCS-010/67 (0%)0/67 (0%)6/67 (9%)
Vehicle0/50 (0%)0/50 (0%)5/50 (10%)
Most frequent other events
Most frequent other events
EventOCS-01Vehicle
Eye inflammationEye disorders6/675/50

Baseline characteristics

The safety population included all randomized participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)OCS-01VehicleTotal
Mean67.9 ± 7.6067.0 ± 7.9367.5 ± 7.72
Sex: Female, Male
Sex: Female, Male(Participants)OCS-01VehicleTotal
Female412768
Male262349
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OCS-01VehicleTotal
Hispanic or Latino251641
Not Hispanic or Latino423476
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OCS-01VehicleTotal
American Indian or Alaska Native101
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American11920
White534093
More than one race000
Unknown or Not Reported000
08

Study locations

24 sites
  • Oculis Investigative Site
    Glendale, California 91204, United States
  • Oculis Investigative Site
    Inglewood, California 90301, United States
  • Oculis Investigative Site
    Newport Beach, California 92663, United States
  • Oculis Investigative Site
    Torrance, California 90505, United States
  • Oculis Investigative Site
    Tamarac, Florida 33321, United States
  • Oculis Investigative Site
    Morrow, Georgia 30260, United States
  • Oculis Investigative Site
    Northbrook, Illinois 60062, United States
  • Oculis Investigative Site
    Indianapolis, Indiana 46240, United States
  • Oculis Investigative Site
    Louisville, Kentucky 40206, United States
  • Oculis Investigative Site
    Woburn, Massachusetts 01810, United States
  • Oculis Investigative Site
    St Louis, Missouri 63131, United States
  • Oculis Investigative Site
    Washington, Missouri 63090, United States
  • Oculis Investigative Site
    Las Vegas, Nevada 89145, United States
  • Oculis Investigative Site
    Elizabeth City, North Carolina 27909, United States
  • Oculis Investigative Site
    Leland, North Carolina 28451, United States
  • Oculis Investigative Site
    Cincinnati, Ohio 45242, United States
  • Oculis Investigative Site
    Eugene, Oregon 97401, United States
  • Oculis Investigative Site
    Erie, Pennsylvania 16507, United States
  • Oculis Investigative Site
    Kingston, Pennsylvania 18704, United States
  • Oculis Investigative Site
    Nashville, Tennessee 37212, United States
  • Oculis Investigative Site
    Austin, Texas 78731, United States
  • Oculis Investigative Site
    Houston, Texas 77008, United States
  • Oculis Investigative Site
    San Antonio, Texas 78229, United States
  • Oculis Investigative Site
    Lynchburg, Virginia 24502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in May 2024, 4 months.

Results were first posted in Jul 2026, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Dec 18, 2023
Primary completionActual
May 2, 2024
CompletionActual
May 9, 2024
Results first posted
Jul 30, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06128369
Lead sponsor
Oculis
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Dec 18, 2023
Primary completion
May 2, 2024
Completion
May 9, 2024
Results posted
Jul 30, 2026
Last update
Jul 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OCS-01

Start the discussion